Stock TCRT ALAUNOS THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Alaunos Therapeutics, Inc.

Equities

TCRT

US98973P2002

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
1.32 USD +13.79% Intraday chart for Alaunos Therapeutics, Inc. +17.86% +24.47%
Apr. 01 Alaunos Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Mar. 05 North American Morning Briefing : S&P 500 Futures -2- DJ

Evolution of the average Target Price on Alaunos Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

275478f6568bb9828b4f6c9b8.2NCFtxtnxejPSmVU-xuUMWAlUAp3wL-0VLOW7N37iVo.sJPx9V4T8om9JR8yl37HSQ1nHEcOht31FfWlgO2I4DnggMjQaiignPkcNA~26a2a3d35657ab3b6776c0d824511d69

Analyst Recommendations on Alaunos Therapeutics, Inc.

HC Wainwright Downgrades Alaunos Therapeutics to Neutral From Buy MT
Laidlaw Downgrades Alaunos Therapeutics to Hold From Buy MT
Wells Fargo Assumes Alaunos Therapeutics at Overweight with $3 Price Target MT
Cantor Fitzgerald Assumes Alaunos Therapeutics at Overweight with $3 Price Target MT
Wells Fargo Upgrades Alaunos Therapeutics to Overweight From Equalweight MT
ZIOPHARM ONCOLOGY : Lake Street Adjusts ZIOPHARM Oncology's Price Target to $3.50 From $7, Maintains Buy Rating MT
ZIOPHARM ONCOLOGY : Raymond James Downgrades ZIOPHARM Oncology to Market Perform From Outperform; Price Target is $3 MT
ZIOPHARM ONCOLOGY : Raymond James Adjusts Price Target on ZIOPHARM Oncology to $4 From $5.50, Maintains Outperform Rating MT
ZIOPHARM ONCOLOGY : Jefferies Downgrades ZIOPHARM Oncology to Hold Rating From Buy, Adjusts Price Target to $5 From $7 MT
ZIOPHARM ONCOLOGY : HC Wainwright Downgrades ZIOPHARM Oncology to Neutral From Buy MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
1.32
Average target price
-

Consensus detail

Consensus revision (last 18 months)

Analysts covering Alaunos Therapeutics, Inc.

HC Wainwright
Laidlaw & Co.
Wells Fargo Securities
Cantor Fitzgerald
Raymond James
Lake Street
Jefferies & Co.

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. TCRT Stock
  4. Consensus Alaunos Therapeutics, Inc.